Stock listing
TPEx:4168 GlycoNex, Inc. (醣聯) 股價
Follow GlycoNex, Inc. into a list and get an email when it puts out news.
Share price · TPEX:4168
$17.55 TWD -1.65 (-8.6%)
Close on Nov 20, 2026
- Day range
- $17.55 – $18.70 TWDNov 20, 2026
- Volume
- 238,489 sharesNov 20, 2026
- Market cap
- $1.97B TWDAt the close on Nov 20, 2026 · price × 112.5M shares outstanding
- 52-week range
- $17.55 – $30.00 TWDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.08M TWDMedian day 87,065 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TPEX:4168 · TWD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $17.55 | -1.65 | -8.6% | $18.00 | $18.70 | $17.55 | 238,489 | |
| $19.20 | -0.50 | -2.5% | $20.00 | $20.00 | $19.00 | 134,110 | |
| $19.70 | +0.20 | +1.0% | $19.50 | $20.05 | $19.05 | 169,819 | |
| $19.50 | -0.80 | -3.9% | $20.30 | $20.65 | $19.30 | 169,639 | |
| $20.30 | 0.00 | 0.0% | $20.05 | $20.35 | $19.90 | 89,410 | |
| $20.30 | -0.60 | -2.9% | $20.90 | $20.90 | $19.75 | 266,144 | |
| $20.90 | -0.25 | -1.2% | $20.50 | $20.95 | $20.50 | 50,572 | |
| $21.15 | +0.15 | +0.7% | $21.10 | $21.45 | $20.75 | 89,036 | |
| $21.00 | +1.05 | +5.3% | $19.95 | $21.30 | $19.95 | 160,297 | |
| $19.95 | -0.35 | -1.7% | $18.30 | $19.95 | $18.30 | 189,404 | |
| $20.30 | -0.45 | -2.2% | $20.55 | $20.85 | $20.00 | 111,036 | |
| $20.75 | -0.25 | -1.2% | $21.00 | $21.00 | $20.00 | 87,703 | |
| $21.00 | -0.25 | -1.2% | $21.25 | $21.25 | $20.40 | 125,153 | |
| $21.25 | -0.05 | -0.2% | $21.00 | $21.30 | $20.90 | 52,313 | |
| $21.30 | -0.15 | -0.7% | $21.30 | $21.30 | $20.90 | 142,273 | |
| $21.45 | -0.05 | -0.2% | $21.50 | $21.80 | $21.25 | 48,702 | |
| $21.50 | 0.00 | 0.0% | $21.50 | $21.50 | $21.30 | 62,366 | |
| $21.50 | +0.05 | +0.2% | $21.30 | $22.05 | $21.05 | 86,427 | |
| $21.45 | 0.00 | 0.0% | $21.45 | $21.45 | $21.45 | 0 | |
| $21.45 | -0.30 | -1.4% | $21.60 | $21.65 | $21.40 | 73,144 | |
| $21.75 | +0.05 | +0.2% | $21.70 | $21.85 | $21.65 | 26,151 | |
| $21.70 | +0.10 | +0.5% | $21.60 | $21.85 | $21.55 | 70,117 | |
| $21.60 | -0.20 | -0.9% | $22.35 | $22.35 | $21.55 | 45,930 | |
| $21.80 | +0.10 | +0.5% | $21.70 | $21.90 | $21.60 | 54,179 | |
| $21.70 | -0.25 | -1.1% | $21.80 | $21.80 | $21.55 | 80,000 | |
| $21.95 | -0.15 | -0.7% | $21.75 | $22.00 | $21.75 | 72,001 | |
| $22.10 | -0.60 | -2.6% | $22.60 | $22.60 | $21.80 | 128,001 | |
| $22.70 | -0.10 | -0.4% | $22.60 | $23.05 | $22.25 | 95,000 | |
| $22.80 | -0.20 | -0.9% | $23.00 | $23.00 | $22.65 | 44,000 | |
| $23.00 | +0.25 | +1.1% | $22.70 | $23.05 | $22.70 | 128,158 | |
| $22.75 | -0.05 | -0.2% | $22.70 | $22.75 | $22.50 | 80,000 | |
| $22.80 | +0.40 | +1.8% | $22.50 | $23.55 | $22.50 | 167,013 | |
| $22.40 | +0.25 | +1.1% | $22.55 | $23.00 | $22.25 | 197,766 | |
| $22.15 | -0.20 | -0.9% | $22.65 | $22.65 | $22.10 | 82,005 | |
| $22.35 | +0.65 | +3.0% | $21.70 | $22.40 | $21.60 | 188,333 | |
| $21.70 | -0.25 | -1.1% | $21.95 | $21.95 | $21.65 | 35,000 | |
| $21.95 | +0.50 | +2.3% | $21.30 | $22.15 | $21.30 | 102,001 | |
| $21.45 | -0.15 | -0.7% | $21.60 | $21.60 | $21.35 | 75,000 | |
| $21.60 | -0.20 | -0.9% | $21.80 | $21.80 | $21.40 | 132,001 | |
| $21.80 | -0.15 | -0.7% | $21.95 | $21.95 | $21.75 | 37,496 | |
| $21.95 | +0.15 | +0.7% | $21.80 | $22.00 | $21.50 | 108,000 | |
| $21.80 | +0.25 | +1.2% | $21.55 | $21.80 | $21.40 | 178,400 | |
| $21.55 | -0.05 | -0.2% | $21.50 | $21.60 | $21.45 | 54,072 | |
| $21.60 | -0.20 | -0.9% | $21.50 | $21.90 | $21.50 | 48,000 | |
| $21.80 | 0.00 | 0.0% | $21.60 | $21.80 | $21.05 | 38,003 | |
| $21.80 | +0.20 | +0.9% | $21.70 | $22.30 | $21.70 | 92,000 | |
| $21.60 | 0.00 | 0.0% | $21.50 | $21.60 | $21.30 | 108,001 | |
| $21.60 | -0.25 | -1.1% | $21.85 | $21.85 | $21.50 | 74,000 | |
| $21.85 | -0.30 | -1.4% | $22.00 | $22.00 | $21.50 | 105,455 | |
| $22.15 | +0.05 | +0.2% | $21.95 | $22.15 | $21.75 | 96,100 | |
| $22.10 | -0.20 | -0.9% | $22.00 | $22.35 | $21.90 | 146,250 | |
| $22.30 | +0.05 | +0.2% | $22.50 | $22.50 | $22.05 | 78,001 | |
| $22.25 | -0.20 | -0.9% | $22.20 | $22.45 | $21.90 | 67,002 | |
| $22.45 | -0.10 | -0.4% | $22.55 | $22.55 | $22.25 | 88,000 | |
| $22.55 | -0.05 | -0.2% | $22.40 | $22.55 | $22.25 | 34,003 | |
| $22.60 | -0.15 | -0.7% | $22.80 | $22.80 | $22.55 | 43,000 | |
| $22.75 | 0.00 | 0.0% | $22.50 | $22.80 | $22.40 | 82,000 | |
| $22.75 | +0.05 | +0.2% | $22.85 | $22.85 | $22.30 | 90,002 | |
| $22.70 | +0.10 | +0.4% | $22.60 | $22.80 | $22.30 | 78,202 | |
| $22.60 | 0.00 | 0.0% | $22.65 | $22.65 | $22.35 | 60,178 | |
| $22.60 | 0.00 | 0.0% | $22.60 | $22.80 | $22.25 | 71,500 | |
| $22.60 | +0.10 | +0.4% | $22.80 | $22.80 | $22.15 | 90,001 |
- Ticker
- TPEx:4168
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TPEx
- Currency
- TWD
What changed lately
Latest news release · Aug 3, 2026
GlycoNex Doses First Patient in Phase I Trial of GNX1021, Advancing Its Glycan-Directed ADC into Clinical Development
Latest deck · Sep 17, 2026
Investor Presentation (September 2026)
Investor deck · 23 slides
Latest news
GlycoNex Doses First Patient in Phase I Trial of GNX1021, Advancing Its Glycan-Directed ADC into Clinical Development
Aug 2, 2026
Closed $22.70 (+2.0%) on Aug 3, 2026
GlycoNex Receives PMDA Approval in Japan to Initiate First-in-Human Phase 1 Trial of GNX1021 in Gastrointestinal Cancers
Apr 14, 2026
Closed $24.45 (+2.7%) on Apr 15, 2026
GlycoNex Inc. and Nippon Kayaku Co., Ltd. Enter Collaboration to Advance Next-Generation ADC Candidate GNX201-ADC
Mar 23, 2026
Closed $24.30 (+3.6%) on Mar 24, 2026
GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program
Dec 8, 2025
Closed $21.80 (+0.9%) on Dec 9, 2025
GlycoNex and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer
Nov 24, 2025
Closed $21.15 (+1.2%) on Nov 25, 2025
GlycoNex, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 5 in the last 12 months · 8 in all · newest Aug 3, 2026 · oldest 2025
- Decks
- 1 deck · latest Sep 17, 2026
Valuation
EV/sales 84.9× against a median of 4.6×: the highest of 9 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.89B TWD
- P/E
- Loss
- EV/sales
- 84.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.3×
- Gross margin
- 41.2%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.6×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| GlycoNex, Inc. · TPEX:4168 | US$59.92M | US$57.21M | n/a | 84.9× | n/a | 2.3× | n/a | 0.6× | n/a |
| Poolbeg Pharma PLC · LSE:POLB | US$61.48M | US$55.17M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| Oncopeptides AB · OMXSTO:ONCO | US$61.34M | US$59.14M | n/a | 6.3× | n/a | 25.1× | −223.6% | 5.4× | n/a |
| vTv Therapeutics Inc. · NASDAQ:VTVT | US$61.33M | −US$15.84M | n/a | −0.4× | n/a | 0.9× | −20.8% | 0.0× | 1.28 |
| ViGenCell, Inc. · KRX:308080 | US$61.08M | US$44.62M | n/a | 65.1× | n/a | 2.1× | n/a | 0.2× | n/a |
| HemoGenyx Pharmaceuticals PLC · LSE:HEMO | US$60.51M | US$56.94M | n/a | n/a | n/a | 10.7× | n/a | 0.4× | n/a |
| Genexine, Inc. · KRX:095700 | US$60.02M | US$44.22M | n/a | 12.0× | n/a | 0.4× | −650.0% | 0.0× | n/a |
| ISU Abxis Co., Ltd. · KRX:086890 | US$59.85M | US$42.29M | n/a | 1.1× | n/a | 0.7× | −16.0% | 0.0× | n/a |
| Rani Therapeutics Holdings, Inc. · NASDAQ:RANI | US$58.99M | US$16.85M | n/a | 2.6× | n/a | 1.7× | −493.0% | 0.1× | 2.21 |
| HeXun Biosciences Co Ltd · TPEX:6986 | US$57.20M | US$32.05M | 16.2× | 3.4× | 6.5× | 1.8× | 37.7% | 0.0× | n/a |
| iNtRON Biotechnology, Inc. · KRX:048530 | US$57.04M | US$31.19M | n/a | 5.8× | n/a | 1.2× | −142.6% | 0.0× | n/a |
| Median of the others | US$60.27M | US$43.25M | 16.2× | 4.6× | 6.5× | 1.8× | −142.6% | 0.0× | 1.75 |
Team and board
Officers
| Officer | Role |
|---|---|
| Mei-Chun Yang | President & CEO |
| Ti-Fen Wu | Chief Financial Officer |
| Tong-Hsuan Chang | Founder & Chairman |
Board
| Director | Role |
|---|---|
| Tong-Hsuan Chang | Founder & Chairman |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2023 | May 31, 2023 | +0.7% |
| Q4 2022 | Mar 1, 2023 | −1.9% |
| Q3 2022 | Nov 30, 2022 | +7.9% |
| Q2 2022 | Aug 31, 2022 | +18.0% |
| Q1 2022 | Jun 1, 2022 | 0.0% |
| Q4 2021 | Mar 2, 2022 | −0.5% |
| Q3 2021 | Dec 1, 2021 | −6.0% |
| Quarter to Jun 30, 2021 | Sep 1, 2021 | +0.9% |
| Quarter to Mar 31, 2021 | Jun 2, 2021 | −5.9% |
| Quarter to Dec 31, 2020 | Mar 3, 2021 | −0.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 23 slides | Sep 17, 2026 |
Financials
Annual, in TWD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 37.9M | 14.7M | 2.54M | 30.1M | 5.47M | 451.0K | 734.0K | 926.0K | 634.0K |
| Cost of revenue | 14.3M | 7.38M | 1.55M | 16.1M | 2.01M | 326.0K | 585.0K | 448.0K | 339.0K |
| Gross profit | 23.5M | 7.32M | 995.0K | 14.0M | 3.46M | 125.0K | 149.0K | 478.0K | 295.0K |
| Research and development | 222.4M | 204.6M | 210.4M | 197.4M | 145.0M | 157.0M | 218.9M | 269.6M | 111.7M |
| Selling, general and administrative | 50.9M | 48.9M | 45.3M | 50.8M | 48.9M | 52.5M | 51.1M | 52.4M | 49.4M |
| Operating income | -249.8M | -246.1M | -158.0M | -215.2M | -172.5M | -158.9M | -269.9M | -321.6M | -160.8M |
| Depreciation and amortization | 35.4M | 34.4M | 31.2M | 40.0M | 40.1M | 46.6M | 54.1M | 55.8M | 52.3M |
| EBITDA | -214.4M | -211.7M | -126.8M | -175.2M | -132.4M | -112.3M | -215.8M | -265.8M | -108.5M |
| Interest expense | 7.04M | 5.71M | 5.71M | 4.36M | 182.0K | 2.48M | 5.00K | 5.00K | 0 |
| Income before tax | -234.1M | -229.7M | -163.7M | -219.8M | -172.5M | -161.4M | -246.7M | -317.6M | -144.1M |
| Income tax | 14.6M | 1.32M | 549.0K | -653.0K | 461.0K | ||||
| Net income | -235.2M | -229.7M | -178.4M | -219.8M | -172.5M | -162.7M | -247.2M | -316.9M | -144.6M |
| Earnings per share, basic | -2.09 | -2.12 | -1.65 | -2.21 | -1.78 | -1.82 | -3.26 | -4.18 | -1.91 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 467.7M | 109.5M | 149.5M | 82.2M | 125.1M | 152.7M | 118.7M | 256.2M | 442.9M |
| Short-term investments | 225.6M | 332.6M | 550.3M | 596.6M | 206.5M | 326.2M | 61.7M | 91.3M | 138.1M |
| Receivables | 2.23M | 0 | 25.0K | 46.0K | 350.0K | 16.0K | 3.43M | 451.0K | 880.0K |
| Current assets | 748.1M | 481.2M | 718.3M | 713.1M | 358.7M | 499.2M | 186.4M | 360.8M | 595.7M |
| Property, plant and equipment | 989.9M | 1.02B | 1.05B | 1.09B | 1.13B | 1.17B | |||
| Total assets | 1.55B | 1.32B | 1.55B | 1.72B | 1.40B | 1.57B | 1.33B | 1.56B | 1.87B |
| Accounts payable | 900.0K | 900.0K | 900.0K | 2.20M | 2.73M | 2.13M | |||
| Current liabilities | 93.5M | 264.6M | 270.6M | 44.5M | 27.2M | 25.6M | 21.5M | 19.8M | 16.9M |
| Long-term debt | 473.6M | 0 | 0 | 218.7M | 0 | 0 | |||
| Total debt | 900.0K | 224.6M | 900.0K | 900.0K | |||||
| Total liabilities | 571.9M | 270.0M | 276.4M | 271.3M | 36.1M | 34.5M | 31.4M | 29.4M | 25.2M |
| Shareholders' equity | 982.3M | 1.05B | 1.28B | 1.45B | 1.36B | 1.54B | 1.30B | 1.53B | 1.84B |
| Shares outstanding | 112.5M | 108.5M | 107.8M | 99.5M | 96.9M | 89.4M | 75.9M | 75.7M | 75.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -166.3M | -222.0M | -183.9M | -167.5M | -140.9M | -145.6M | -179.6M | -180.3M | 61.4M |
| Capital spending | -6.58M | -35.3M | -23.4M | -8.69M | -6.84M | -1.87M | -1.50M | -3.22M | -235.6M |
| Free cash flow | -172.9M | -257.2M | -207.3M | -176.2M | -147.7M | -147.5M | -180.8M | -183.6M | -192.6M |
| Cash from investing | -399.6M | 113.2M | -199.7M | 28.0M | -7.54M | -252.5M | |||
| Cash from financing | -6.72M | 524.2M | -27.0K | 379.3M | 14.1M | 1.12M | 2.98M | ||
| Share buybacks | 0 | ||||||||
| Change in cash | 358.2M | -40.0M | 67.3M | -42.9M | -27.7M | 34.0M | -137.4M | -186.8M | -188.1M |
Cap table
Built by 6ix from GlycoNex, Inc.’s releases
- Common shares
- 112,521,000
- Fully diluted
- 112,521,000
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 112,521,000 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 112,521,000 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Mei-Chun Yang | President & CEO · Since at least Aug 3, 2026 |
| Ti-Fen Wu | Chief Financial Officer · Since at least Nov 5, 2026 |
| Tong-Hsuan Chang | Founder & Chairman · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about GlycoNex, Inc.